NasdaqCM:CAPRBiotechs
Assessing Capricor Therapeutics After a 343% Surge and Bullish DCF Valuation Estimate
If you have been wondering whether Capricor Therapeutics is still a smart buy after its big run, you are not alone. This stock has quickly moved from under the radar to front and center on a lot of watchlists.
The share price has dipped 3.2% over the last week, but that small pullback sits on top of a 343.3% gain in the last month and a 96.2% return over the past year, with long term holders still up 593.9% over 3 years and 524.0% over 5 years.
Behind those moves, investors have been...